151 results about "Psychiatric Disease" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Compositions comprising microalgal extracellular vesicles (MEVs) formulated for intranasal delivery are provided, whereby upon intranasal administration, the MEVs are transported by a specific route, to specific regions in the brain via the olfactory nerve after intranasal administration, and to interconnected brain regions through the lateral olfactory tract (LOT). The MEVs are transported via neuronal axonal transport. The MEVs have the ability to cross synapses including: (i) synapses between olfactory sensory neurons (OSNs) and mitral / tufted neurons; (ii) synapses between mitral / tufted neurons and local neurons in multiple brain regions colonized by the lateral olfactory tract (LOT); and (iii) synapses between neurons in brain regions colonized by the LOT and neurons from the frontal cortex, hippocampus, thalamus, and hypothalamus. The compositions contain extracellular vesicles (MEVs) from microalgae loaded with bioactive cargo for the treatment, detection, diagnosis, or monitoring of diseases, disorders, or conditions of or involving the brain, particularly neuronal delivery of the cargo. The compositions and methods have multiple applications as therapeutic and diagnostic agents for the treatment, diagnosis, and monitoring of diseases, disorders, or conditions of or involving the brain. The compositions can be used in methods and uses for the treatment of cancers involving the brain, and can be used, for example, to deliver therapeutic agents for psychiatric diseases, disorders, conditions, and to deliver therapeutic agents for neurodegenerative diseases, disorders, and conditions.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention provides a mental disease classification method and system based on an individual difference structure covariant network and machine learning, and belongs to the field of mental disease classification. The problem of classification performance bottleneck caused by heterogeneity of mental diseases in the prior art is solved. The method comprises the following steps: acquiring a structural magnetic resonance T1 weighted image, and preprocessing the image; performing brain region segmentation on the pre-processed T1 image based on an AAL brain map, and extracting the gray matter volume of each brain region; constructing an IDSCN network by calculating the Pearson's correlation coefficient of the brain grey matter volume of the paired brain regions; calculating the area under a node topological attribute curve of the IDSCN network; screening node attribute indexes with statistical differences between the patient group and the healthy control group through double-sample t test; and taking the screened node attribute indexes as feature vectors, and inputting the feature vectors into a support vector machine classification model for disease classification. The method is mainly used in the medical image processing field.

The invention relates to the technical field of psychiatric disease diagnosis, and discloses a defective schizophrenia prediction and analysis system based on multi-modal brain network characteristics, which comprises an image data acquisition module, an image data processing module, a deep learning model module and a prediction module which are connected in sequence, the image data acquisition module acquires a brain MRI image; the image data processing module carries out cortical and subcortical reconstruction on the brain MRI image to obtain a model input index; the deep learning model module performs training by using a training data set composed of a plurality of brain MRI images and defective schizophrenia diagnosis results thereof to obtain a target prediction model; and the prediction module inputs the real-time brain MRI image into the target prediction model to obtain a prediction result. According to the method, the multi-dimensional brain structure image features are integrated, diagnosis information contained in brain region changes is fully mined, prediction results of defective schizophrenia and non-defective schizophrenia are improved, and a more comprehensive biological basis is provided for clinical diagnosis.

This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.

Systems and methods for the identification of auto-antibodies associated with central nervous system or psychiatric disease or disorders. Also disclosed herein are methods of treating central nervous system or psychiatric disease or disorders associated with auto-antibodies.

There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.

The present invention relates to compounds having a fused, substituted tricyclic scaffold and stereo-isomeric forms, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted tricyclic derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said substituted tricyclic derivatives have been identified as especially potent ligands of FK506 binding proteins (FKBPs), especially human FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMip, CtMip, CpMip, NgMip, KpMip, BpMip, TcMip, EcFKLB, EcFKPA, PaFKLB, PaFKPA, AbFKLB, AbFKPA, and are useful for treatment of diseases such as psychiatric, metabolic, infective, neurological and haematological disorders as well as pain and cancers and as anti-inflammatory drugs. Said substituted tricyclic derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues.

An upper arm restraining device for mental patient nursing comprises a restraining belt, a first arm fixing frame and a second arm fixing frame, the outer side of the restraining belt is connected with the first arm fixing frame, the first arm fixing frame slides on the restraining belt, the outer side of the restraining belt is connected with the second arm fixing frame, and the second arm fixing frame slides on the restraining belt. The first arm fixing frame and the second arm fixing frame are symmetrically arranged, the first arm fixing frame comprises a first restraint frame and a second restraint frame, the inner side of the first restraint frame is connected with the second restraint frame, the second restraint frame slides in the first restraint frame, and the first restraint frame comprises a first positioning plate, a first auxiliary fastening arm, a first auxiliary connecting arm and a first binding belt. Operation is easy, adjustment is convenient, the application range is wide, the restraining effect is good, the mental patient is effectively prevented from hurting himself or herself and medical staff due to the fact that arms of the mental patient move randomly in the morbidity process, and the structure is stable and reasonable.

The present disclosure provides azocino[4,5,6-cd]indoles as serotonin receptor modulators. Uses of said compounds in the treatment of medical disorders, such as neurological or psychiatric disorders, and processes of synthesizing said compounds are also provided.

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

The invention establishes a rapid, accurate and efficient high performance liquid chromatography-mass spectrometry detection method for detecting the common antipsychotic drugs in the hair, and the concentration of ten common antipsychotic drugs or metabolites in the hair can be quantitatively detected at the same time; the method is suitable for clinical blood concentration monitoring, drug poisoning screening and large-scale biological sample detection, and has very significant significance in clinical use.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present application relates to methods of activating intracellular serotonin receptors using indoline derivatives of general formula (I) or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, and to the treatment of diseases, disorders or conditions by activating intracellular serotonin receptors. The diseases, disorders, or conditions include, for example, psychosis, mental disorders, and CNS disorders. The invention also relates to a novel indoline derivative as well as a composition and application thereof. Wherein Q is selected from (Q1), (Q2), (Q3), (Q4), (Q5) and (Q6). # imgabs0 #

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

Provided are methods of treating a neurological or psychiatric disease or disorder, methods of treating behavioral problems associated with a neurological or psychiatric disease or disorder, and methods of improving behavioral and / or psychological symptoms of a neurological or psychiatric disease or disorder in a subject in need thereof.

The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

The present invention relates to macrocyclic FKBP51-binding compounds having improved characteristics, as well as solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and / or diluents. Said compounds have been identified as especially potent ligands of FK506 binding proteins (FKBPs also called MIPs in bacteria), especially human FKBP51 and are useful for treatment of diseases such as psychiatric, metabolic and neurological disorders as well as pain and cancers. Said substituted derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues (FIG. 10).

The invention discloses a composition, a method and a system for predicting the applicability of antipsychotic drugs. The invention develops a composition, a detection kit, a model construction method and a system for predicting the applicability of antipsychotic drugs on the basis of selected SNP site information. Particularly, a gene marker combination related to the curative effects of the antipsychotic drugs olanzapine, risperidone, aripiprazole and quetiapine is found by adopting a large-sample high-throughput whole-genome association analysis technology, and a corresponding mathematical model for predicting the curative effects is constructed; the model can be used for predicting the PANSS subtraction rate after the schizophrenia is treated by medication based on DNA polymorphic sites and clinical basic information of a medication user in a high, medium and low classification manner, and assists in guiding the selection of the types of the medication, so that personalized treatment of the schizophrenia patient is realized.

The present invention relates to novel compounds of Formula (I), (I), wherein P, Q, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which GABAB-R is involved.

The present invention relates to an apparatus for treating neurological or psychiatric disorders using i-wave periodicity-dependent Quadri-Pulse Theta Burst Stimulation (iQPS). The system comprises a transcranial magnetic stimulation (TMS) stimulator configured to deliver test pulses to a target motor cortical area and therapeutic theta bursts to a treatment area with pulse frequency tailored to the patient's individual i-wave periodicity. An electromyography (EMG) device records motor evoked potentials (MEPs) from a target muscle and analyzes the intervals between MEPs to determine the i-wave periodicity. The personalized stimulation enhances cortical plasticity by synchronizing stimulation with the brain's intrinsic neural timing. The invention is applicable to neurological and psychiatric conditions that include depression, schizophrenia, stroke recovery and neuropathic pain. Advantages include improved treatment efficacy, reduced variability in patient response and a non-invasive, adaptive therapy model that aligns with the patient's unique neurophysiological characteristics, offering a precise and scalable approach to brain stimulation.

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for feeling abnormal, tremor, or tinnitus, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops feeling abnormal, subcutaneous tissue disorder, tremor, or tinnitus.

Disclosed in the present invention is a wearable psychiatric patient restraint apparatus, relating to the technical field of psychiatric patient care apparatuses. The wearable psychiatric patient restraint apparatus comprises an apparatus main body and a restraint strap. A sliding block is movably mounted at the top end of the apparatus main body, and a restraint mechanism is disposed between a pulley block and the sliding block. A protective pad is fixedly mounted on an inner side surface of the restraint strap, a moving block is movably mounted on an inner side surface of the apparatus main body, and an adjustment mechanism is disposed between the protective pad and the moving block. According to the wearable psychiatric patient restraint apparatus, a drive motor works to drive a drive shaft to drive a spiral member to rotate, and the spiral member drives the sliding block to drive a support plate to move, so that the position of the restraint strap is conveniently adjusted, a patient is conveniently restrained at a comfortable position, and the psychological pressure of the patient is reduced, thereby making it convenient for the nursing staff to dress a patient. Moreover, the protective pad on the inner side of the restraint strap is used for protecting the wrists and ankles of the psychiatric patient, thereby reducing the wear of the wrists and ankles of the patient.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.